{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Matching+Oral+Placebo&page=40",
    "query": {
      "intervention": "Matching Oral Placebo",
      "page": 40
    },
    "page_size": 10
  },
  "pagination": {
    "page": 40,
    "page_size": 10,
    "total_count": 3459,
    "total_pages": 346,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Matching+Oral+Placebo&page=41&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Matching+Oral+Placebo&page=39&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-16T15:14:53.423Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT07288138",
      "title": "A Study of a Thyroid Hormone Receptor Beta Isoform (THRβ) Agonist and an Semicarbazide Sensitive Amine Oxidase (SSAO) Inhibitor, Alone and in Combination, in Adults With Presumed Metabolic Dysfunction-associated Steatohepatitis (MASH)",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Metabolic Dysfunction-associated Steatohepatitis"
      ],
      "interventions": [
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "ECC4703",
          "type": "DRUG"
        },
        {
          "name": "ECC0509",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Eccogene",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 160,
      "start_date": "2025-12-15",
      "completion_date": "2027-09-29",
      "has_results": false,
      "last_update_posted_date": "2026-10-09",
      "last_synced_at": "2026-10-16T15:14:53.423Z",
      "location_count": 68,
      "location_summary": "Chandler, Arizona • Peoria, Arizona • Tucson, Arizona + 58 more",
      "locations": [
        {
          "city": "Chandler",
          "state": "Arizona"
        },
        {
          "city": "Peoria",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07288138"
    },
    {
      "nct_id": "NCT03334721",
      "title": "Gabapentin for Bipolar & Cannabis Use Disorders",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Bipolar I Disorder",
        "Bipolar II Disorder",
        "Cannabis Use Disorder",
        "Substance Use Disorders"
      ],
      "interventions": [
        {
          "name": "Gabapentin",
          "type": "DRUG"
        },
        {
          "name": "Placebo Oral Capsule",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Medical University of South Carolina",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 23,
      "start_date": "2017-10-01",
      "completion_date": "2019-07-01",
      "has_results": true,
      "last_update_posted_date": "2020-11-13",
      "last_synced_at": "2026-10-16T15:14:53.423Z",
      "location_count": 1,
      "location_summary": "Charleston, South Carolina",
      "locations": [
        {
          "city": "Charleston",
          "state": "South Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03334721"
    },
    {
      "nct_id": "NCT03379506",
      "title": "Elbasvir (EBR)/Grazoprevir (GZR) in Pediatric Participants With Chronic Hepatitis C Infection (MK-5172-079)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "HCV Infection"
      ],
      "interventions": [
        {
          "name": "EBR/GZR FDC Tablet",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "Grazoprevir Oral Granules",
          "type": "DRUG"
        },
        {
          "name": "Elbasvir Oral Granules",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Merck Sharp & Dohme LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "3 Years",
        "maximum_age": "17 Years",
        "sex": "ALL",
        "summary": "3 Years to 17 Years"
      },
      "enrollment_count": 57,
      "start_date": "2018-01-25",
      "completion_date": "2020-07-23",
      "has_results": true,
      "last_update_posted_date": "2023-05-31",
      "last_synced_at": "2026-10-16T15:14:53.423Z",
      "location_count": 8,
      "location_summary": "San Francisco, California • Orlando, Florida • Atlanta, Georgia + 5 more",
      "locations": [
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Orlando",
          "state": "Florida"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Cincinnati",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03379506"
    },
    {
      "nct_id": "NCT01335464",
      "title": "Safety and Efficacy of BIBF 1120 at High Dose in Idiopathic Pulmonary Fibrosis Patients",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Pulmonary Fibrosis"
      ],
      "interventions": [
        {
          "name": "placebo",
          "type": "DRUG"
        },
        {
          "name": "BIBF 1120",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Boehringer Ingelheim",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "40 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "40 Years and older"
      },
      "enrollment_count": 515,
      "start_date": "2011-04",
      "completion_date": "2013-10",
      "has_results": true,
      "last_update_posted_date": "2016-07-25",
      "last_synced_at": "2026-10-16T15:14:53.423Z",
      "location_count": 24,
      "location_summary": "Birmingham, Alabama • Jasper, Alabama • Phoenix, Arizona + 20 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Jasper",
          "state": "Alabama"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Danbury",
          "state": "Connecticut"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01335464"
    },
    {
      "nct_id": "NCT03226899",
      "title": "A Phase 4 Safety and Efficacy Study to Evaluate Lesinurad 200 mg in Participants With Gout and Renal Impairment",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Gout",
        "Chronic Kidney Disease (CKD)"
      ],
      "interventions": [
        {
          "name": "Lesinurad",
          "type": "DRUG"
        },
        {
          "name": "XOI",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "colchicine",
          "type": "DRUG"
        },
        {
          "name": "corticosteroids",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Ironwood Pharmaceuticals, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "85 Years",
        "sex": "ALL",
        "summary": "18 Years to 85 Years"
      },
      "enrollment_count": 242,
      "start_date": "2017-07-19",
      "completion_date": "2019-02-25",
      "has_results": true,
      "last_update_posted_date": "2021-11-04",
      "last_synced_at": "2026-10-16T15:14:53.423Z",
      "location_count": 70,
      "location_summary": "Birmingham, Alabama • Tucson, Arizona • Covina, California + 59 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Covina",
          "state": "California"
        },
        {
          "city": "Sacramento",
          "state": "California"
        },
        {
          "city": "Sacramento",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03226899"
    },
    {
      "nct_id": "NCT05924321",
      "title": "A Study to Evaluate the Effect of Carbetocin on the QT/QTc Interval in Healthy Subjects",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Postpartum Hemorrhage"
      ],
      "interventions": [
        {
          "name": "Carbetocin",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "Placebo and Moxifloxacin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Ferring Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "45 Years",
        "sex": "ALL",
        "summary": "18 Years to 45 Years"
      },
      "enrollment_count": 40,
      "start_date": "2023-05-25",
      "completion_date": "2023-09-21",
      "has_results": false,
      "last_update_posted_date": "2024-09-03",
      "last_synced_at": "2026-10-16T15:14:53.423Z",
      "location_count": 1,
      "location_summary": "Tempe, Arizona",
      "locations": [
        {
          "city": "Tempe",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05924321"
    },
    {
      "nct_id": "NCT05894564",
      "title": "ACTIV-6: COVID-19 Study of Repurposed Medications - Arm E (Fluvoxamine 100)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Covid19"
      ],
      "interventions": [
        {
          "name": "Fluvoxamine",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Susanna Naggie, MD",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "30 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "30 Years and older"
      },
      "enrollment_count": 1208,
      "start_date": "2022-08-25",
      "completion_date": "2023-05-30",
      "has_results": true,
      "last_update_posted_date": "2024-11-15",
      "last_synced_at": "2026-10-16T15:14:53.423Z",
      "location_count": 103,
      "location_summary": "Gilbert, Arizona • Mesa, Arizona • Peoria, Arizona + 90 more",
      "locations": [
        {
          "city": "Gilbert",
          "state": "Arizona"
        },
        {
          "city": "Mesa",
          "state": "Arizona"
        },
        {
          "city": "Peoria",
          "state": "Arizona"
        },
        {
          "city": "Newport Beach",
          "state": "California"
        },
        {
          "city": "North Hollywood",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05894564"
    },
    {
      "nct_id": "NCT05449444",
      "title": "Masitinib for the Treatment of Severe Mast Cell Activation Syndrome",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Mast Cell Activation Syndrome"
      ],
      "interventions": [
        {
          "name": "Masitinib 4.5 mg/kg/day",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "Best supportive care",
          "type": "OTHER"
        },
        {
          "name": "Masitinib 6.0 mg/kg/day",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "AB Science",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 72,
      "start_date": "2022-07-01",
      "completion_date": "2024-12-31",
      "has_results": false,
      "last_update_posted_date": "2023-02-06",
      "last_synced_at": "2026-10-16T15:14:53.423Z",
      "location_count": 1,
      "location_summary": "Weldon Spring, Missouri",
      "locations": [
        {
          "city": "Weldon Spring",
          "state": "Missouri"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05449444"
    },
    {
      "nct_id": "NCT03404206",
      "title": "A Trial to Compare the Duration of Analgesic Efficacy and Safety of Naproxen Sodium Tablets and Ibuprofen Tablets in Postsurgical Dental Pain",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Pain, Postoperative"
      ],
      "interventions": [
        {
          "name": "Naproxen Sodium (Aleve, BAY117031)",
          "type": "DRUG"
        },
        {
          "name": "Ibuprofen (Advil)",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Bayer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "16 Years",
        "maximum_age": "40 Years",
        "sex": "ALL",
        "summary": "16 Years to 40 Years"
      },
      "enrollment_count": 387,
      "start_date": "2018-02-12",
      "completion_date": "2018-07-10",
      "has_results": true,
      "last_update_posted_date": "2019-07-18",
      "last_synced_at": "2026-10-16T15:14:53.423Z",
      "location_count": 1,
      "location_summary": "Salt Lake City, Utah",
      "locations": [
        {
          "city": "Salt Lake City",
          "state": "Utah"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03404206"
    },
    {
      "nct_id": "NCT01217814",
      "title": "Effect of SAR153191 (REGN88) With Methotrexate in Patients With Active Rheumatoid Arthritis Who Failed TNF-α Blockers",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Rheumatoid Arthritis"
      ],
      "interventions": [
        {
          "name": "Sarilumab",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "Golimumab",
          "type": "DRUG"
        },
        {
          "name": "methotrexate (MTX)",
          "type": "DRUG"
        },
        {
          "name": "Folic/folinic acid",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Sanofi",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 16,
      "start_date": "2010-11",
      "completion_date": "2011-09",
      "has_results": true,
      "last_update_posted_date": "2017-09-01",
      "last_synced_at": "2026-10-16T15:14:53.423Z",
      "location_count": 4,
      "location_summary": "Freehold, New Jersey • New York, New York • Jackson, Tennessee + 1 more",
      "locations": [
        {
          "city": "Freehold",
          "state": "New Jersey"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "Jackson",
          "state": "Tennessee"
        },
        {
          "city": "Austin",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01217814"
    }
  ]
}